Media coverage about Athenex (NASDAQ:ATNX) has trended somewhat positive on Sunday, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Athenex earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.7265524459922 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Shares of Athenex (ATNX) traded down $0.08 during trading on Friday, reaching $16.77. The company had a trading volume of 87,242 shares, compared to its average volume of 111,011. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.78 and a quick ratio of 3.44. Athenex has a 52 week low of $11.21 and a 52 week high of $20.79.
Athenex (NASDAQ:ATNX) last posted its quarterly earnings data on Monday, August 14th. The company reported ($0.88) earnings per share for the quarter. The business had revenue of $4.60 million for the quarter. research analysts predict that Athenex will post -1.69 earnings per share for the current year.
ATNX has been the subject of several research analyst reports. Laidlaw initiated coverage on Athenex in a research report on Tuesday, September 19th. They set a “buy” rating and a $36.00 target price for the company. Deutsche Bank AG initiated coverage on Athenex in a research report on Monday, July 10th. They set a “buy” rating and a $20.00 target price for the company. J P Morgan Chase & Co initiated coverage on Athenex in a research report on Wednesday, October 18th. They set a “neutral” rating and a $22.20 target price for the company. Credit Suisse Group initiated coverage on Athenex in a research report on Monday, September 18th. They set an “outperform” rating and a $25.00 target price for the company. Finally, Royal Bank Of Canada initiated coverage on Athenex in a research report on Thursday, September 14th. They set an “outperform” rating and a $35.00 target price for the company. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $27.64.
COPYRIGHT VIOLATION NOTICE: “Athenex (ATNX) Earning Somewhat Positive News Coverage, Study Shows” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://www.com-unik.info/2017/11/05/athenex-atnx-earning-somewhat-positive-news-coverage-study-shows.html.
Athenex Company Profile
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
What are top analysts saying about Athenex Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Athenex Inc. and related companies.